The specialist engages academic centers, biopharma, clinical diagnostics labs, and emerging clinical partners to drive technology evaluation, workflow adoption, and clinical implementation. They serve as a trusted advisor to key decision-makers, collaborate closely with cross-functional teams, and play a critical role in achieving regional revenue growth and strategic market expansion for the oncology segment in APAC.
Duties include, but are not limited to:
- Commercial Strategy & Execution
· Develop and execute segment focused strategic account and territory plans with territory account managers to achieve or exceed revenue targets
· Accelerate opportunities across academic research, translational labs, biopharma, and oncology testing providers
· Partner with Account Managers, Field Application Scientists, and Customer Care to ensure seamless customer experience
· Manage pipeline and forecasting using CRM tools; track progress and analyse performance metrics
- Customer & Market Engagement
· Build and maintain relationships with key opinion leaders (KOLs), senior scientists, clinicians, pathologists, and decision-makers
· Provide consultative guidance on study design, workflows, assay development, clinical validation, and bioinformatics analysis
· Stay current on oncology research trends, clinical, regulatory, operational, and commercial dynamics that shape adoption decisions
· Represent ONT at conferences, symposia, and customer events; deliver seminars, workshops, and technical briefings
- Cross-Functional Collaboration
· Partner with Marketing, Business Development, Inside Sales, and FAS teams to execute segment-specific go-to-market plans
· Align with Field Marketing, Product Management, and Inside Sales to refine messaging, content, and campaigns for the oncology audience
· Deliver structured customer and market feedback to inform product roadmap and commercial strategy
- Market Intelligence & Leadership
· Monitor and report competitor activities, emerging technologies, and oncology assay development trends
· Contribute to oncology segment strategy and sales enablement initiatives
· Support community building and long-term customer success through engagement, education, and advocacy.
Preferred Background
· MSc or PhD in Genomics, Molecular Biology, Immunology, Cell Biology, or related field.
· Regional cancer research and oncology testing market knowledge.
· 8+ years of genomics/commercial experience, preferably in oncology or sequencing-based diagnostics
· Proven track record selling complex research technologies (e.g., NGS, multi-omics platforms) and oncology testing solutions (germline + somatic)
· Strong network and experience engaging KOLs, senior researchers, clinicians, and lab directors across leading academic and clinical centers
· Deep understanding of oncology research trends, clinical workflows, regulatory and reimbursement environments
· Strategic, analytical, and consultative selling mindset with strong influence and negotiation capabilities
· Excellent communication and presentation skills across scientific and business audiences
· Experience using CRM tools (e.g., Salesforce)
· Ability to travel up to ~70% across the APAC region
#LI-MW1
About UsOxford Nanopore Technologies: Our goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for faster, information rich, accessible and affordable molecular analysis. The first application is DNA/RNA sequencing, and the technology is in development for the analysis of other types of molecules including proteins. The technology is used to understand and characterise the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. With a thriving culture of ambition and strong innovation goals, Oxford Nanopore is a UK headquartered company with global operations and customers in more than 125 countries.
Skills Required
- MSc or PhD in Genomics, Molecular Biology, Immunology, Cell Biology, or related field
- 8+ years of genomics/commercial experience, preferably in oncology or sequencing-based diagnostics
- Proven track record selling complex research technologies
- Strong network and experience engaging KOLs, senior researchers, clinicians, and lab directors
- Experience using CRM tools (e.g., Salesforce)
Oxford Nanopore Technologies Compensation & Benefits Highlights
The following summarizes recurring compensation and benefits themes identified from responses generated by popular LLMs to common candidate questions about Oxford Nanopore Technologies and has not been reviewed or approved by Oxford Nanopore Technologies.
-
Fair & Transparent Compensation — Pay is considered good to above average across many roles, with employer-provided ranges visible for several U.S. commercial and applications positions and company materials emphasizing market‑competitive base pay. Commercial and some senior technical posts, particularly in the U.S., are positioned as competitive and often paired with strong variable components.
-
Equity Value & Accessibility — All‑employee share plans in the UK and a U.S. employee stock purchase plan indicate broad access to equity as part of total reward. Company communications highlight attractive bonus and share plans that add meaningful upside beyond base pay.
-
Healthcare Strength — U.S. roles indicate strong health insurance and core protections, while official materials and country overviews reference private medical coverage and wellbeing support. These elements position the health package as a notable strength alongside cash compensation.
Oxford Nanopore Technologies Insights
What We Do
Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society. Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide. Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.
